Tolvaptan for the treatment of liver cirrhosis oedema

References

• D’Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006;44(1):217-31
   PubMed Web of Science ®Google Scholar
• Planas R, Montoliu S, Ballesté B, et al. Natural history of patients hospitalized for management of cirrhotic ascites. Clin Gastroenterol Hepatol 2006;4(11):1385-94
   PubMed Web of Science ®Google Scholar
• Ginès P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance, and management. Hepatology 2008;48(3):1002-10
   PubMed Web of Science ®Google Scholar
• Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008;359(10):1018-26
   PubMed Web of Science ®Google Scholar
• Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334(11):693-9
   PubMed Web of Science ®Google Scholar
• Gao F, Gao R, Li G, et al. Health-related quality of life and survival in Chinese patients with chronic liver disease. Health Qual Life Outcomes 2013;11(1):131
   PubMedGoogle Scholar
• Doggrell SA. Tolvaptan (Otsuka). Curr Opin Investig Drugs 2004;5(9):977-83
   PubMedGoogle Scholar
• Gines P, Wong F, Watson H, et al. Effects of satavaptan, a selective vasopressin V2 receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: a randomized trial. Hepatology 2008;48(1):204-13
   PubMed Web of Science ®Google Scholar
• Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355(20):2099-112
   PubMed Web of Science ®Google Scholar
• Sawyer WH, Pang PK, Seto J, et al. Vasopressin analogs that antagonize antidiuretic responses by rats to the antidiuretic hormone. Science 1981;212(4490):49-51
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Ogawa H, Yamashita H, et al. Characterization of a novel aquaretic agent, OPC-31260, as an orally effective, nonpeptide vasopressin V2 receptor antagonist. Br J Pharmacol 1992;105(4):787-91
   PubMed Web of Science ®Google Scholar
• Yamamura Y, Nakamura S, Itoh S, et al. OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats. J Pharmacol Exp Ther 1998;287(3):860-7
   PubMed Web of Science ®Google Scholar
• Matsuzaki M, Hori M, Izumi T, et al. Efficacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011;25(suppl 1):S33-45
   PubMedGoogle Scholar
• Okita K, Sakaida I, Okada M, et al. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated hepatic cirrhosis. J Gastroenterol 2010;45(9):979-87
   PubMed Web of Science ®Google Scholar
• Sakaida I, Yanase M, Kobayashi Y, et al. ASCITES Clinical Pharmacology Group. The pharmacokinetics and pharmacodynamics of tolvaptan in patients with liver cirrhosis with insufficient response to conventional diuretics: a multicentre, double-blind, parallel-group, phase III study. J Int Med Res 2012;40(6):2381-93
   PubMedGoogle Scholar
• Sakaida I, Yamashita S, Kobayashi T, et al. ASCITES 14-Day Administration Study Group. Efficacy and safety of a 14-day administration of tolvaptan in the treatment of patients with ascites in hepatic oedema. J Int Med Res 2013;41(3):835-47
   PubMedGoogle Scholar
• Okita K, Kawazoe S, Hasebe C, et al. ASCITES Dose-Finding Trial Group. Dose-finding trial of tolvaptan in liver cirrhosis patients with hepatic edema: a randomized, double-blind, placebo-controlled trial. Hepatol Res 2014;44(1):83-91
   PubMedGoogle Scholar
• Sakaida I, Kawazoe S, Kajimura K, et al. ASCITES-DOUBLEBLIND Study Group. Tolvaptan for improvement of hepatic edema: a phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol Res 2014;44(1):73-82
   PubMedGoogle Scholar
• Cárdenas A, Ginès P, Marotta P, et al. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J Hepatol 2012;56(3):571-8
   PubMedGoogle Scholar
• Shoaf SE, Bricmont P, Mallikaarjun S. Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects. Br J Clin Pharmacol 2012;73(4):579-87
   PubMed Web of Science ®Google Scholar
• Furukawa M, Umehara K, Kashiyama E. Nonclinical pharmacokinetics of a new nonpeptide V2 receptor antagonist. Tolvaptan Cardiovasc Drugs Ther 2011;25(suppl 1):S83-9
   Google Scholar
• Shoaf SE, Bricmont P, Mallikaarjun S. Absolute bioavailability of tolvaptan and determination of minimally effective concentrations in healthy subjects. Int J Clin Pharmacol Ther 2012;50(2):150-6
   PubMedGoogle Scholar
• Kim SR, Hasunuma T, Sato O, et al. Pharmacokinetics, pharmacodynamics and safety of tolvaptan, a novel, oral, selective nonpeptide AVP V2-receptor antagonist: results of single- and multiple-dose studies in healthy Japanese male volunteers. Cardiovasc Drugs Ther 2011;25(suppl 1):S5-S17
   PubMedGoogle Scholar
• Shoaf SE, Wang Z, Bricmont P, et al. Pharmacokinetics, pharmacodynamics, and safety of tolvaptan, a nonpeptide AVP antagonist, during ascending single-dose studies in healthy subjects. J Clin Pharmacol 2007;7(12):1498-507
   Google Scholar
• Oriuchi N, Nakajima T, Mochiki E, et al. A new, accurate and conventional five-point method for quantitative evaluation of ascites using plain computed tomography in cancer patients. Jpn J Clin Oncol 2005;35(7):386-90
   PubMed Web of Science ®Google Scholar
• Sakaida I, Okita K. Correlation between changes in bodyweight and changes in ascites volume in liver cirrhosis patients with hepatic edema in short-term diuretic therapy. Hepatol Res 2014;44(1):73-82
   PubMedGoogle Scholar
• EASL clinical practice guidelines on the management of ascites. spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. European Association for the Study of the Liver. J Hepatol 2010;53(3):397-417
   PubMedGoogle Scholar
• Gine`s P, Berl T, Bernardi M, et al. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology 1998;28(3):851-64
   PubMedGoogle Scholar
• Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005;11(3):336-43
   PubMed Web of Science ®Google Scholar
• Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004;40(4):802-10
   PubMed Web of Science ®Google Scholar
• Biggins SW, Rodriguez HJ, Bacchetti P, et al. Serum sodium predicts mortality in patients listed for liver transplantation. Hepatology 2005;41(1):32-9
   PubMed Web of Science ®Google Scholar
• Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006;130(6):1652-60
   PubMed Web of Science ®Google Scholar
• Wong F. Drug insight: the role of albumin in the management of chronic liver disease. Nat Clin Pract Gastroenterol Hepatol 2007;4(1):43-51
   PubMedGoogle Scholar
• Cárdenas A, Arroyo V. Mechanisms of water and sodium retention in cirrhosis and the pathogenesis of ascites. Best Pract Res Clin Endocrinol Metab 2003;17(4):607-22
   PubMed Web of Science ®Google Scholar
• Gentilini P, Casini-Raggi V, Di Fiore G, et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J Hepatol 1999;30(4):639-45
   PubMed Web of Science ®Google Scholar
• Romanelli RG, La Villa G, Barletta G, et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World J Gastroenterol 2006;12(9):1403-7
   PubMed Web of Science ®Google Scholar
• Inoue M, Okajima K, Itoh K, et al. Mechanism of furosemide resistance in analbuminemic rats and hypoalbuminemic patients. Kidney Int 1987;32(2):198-203
   PubMed Web of Science ®Google Scholar
• Evans TW. Review article: albumin as a drug-biological effects of albumin unrelated to oncotic pressure. Aliment Pharmacol Ther 2002;16(suppl 5):6-11
   PubMedGoogle Scholar
• Péron JM, Bureau C, Gonzalez L, et al. Treatment of hepatorenal syndrome as defined by the international ascites club by albumin and furosemide infusion according to the central venous pressure: a prospective pilot study. Am J Gastroenterol 2005;100(12):2702-7
   PubMedGoogle Scholar
• Wong F, Gines P, Watson H, et al. Effects of a selective vasopressin V2 receptor antagonist, satavaptan, on ascites recurrence after paracentesis in patients with cirrhosis. J Hepatol 2010;53(2):283-90
   PubMedGoogle Scholar